Profile of suvorexant in the management of insomnia

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 6035-

  Sutton, Eliza L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Dual orexin receptor antagonist; Hypnotic; Hypocretin; Insomnia; Orexin

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 3A INHIBITOR; OREXIN; SUVOREXANT; AZEPINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABNORMAL DREAMING; AGE; ARTICLE; CATAPLEXY; DAYTIME SOMNOLENCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONCENTRATION; DRUG CONTRAINDICATION; DRUG INFORMATION; FATIGUE; FOOD DRUG INTERACTION; GENDER; HALLUCINATION; HUMAN; INSOMNIA; KIDNEY FAILURE; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; NARCOLEPSY; NEUROBIOLOGY; NONHUMAN; OBESITY; PARASOMNIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; SEDATION; SIDE EFFECT; SUICIDAL IDEATION; CHEMISTRY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

AZEPINES; HUMANS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZOLES;

EID: 84947104858     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S73224     Document Type: Article

References (61)

1. United States Food and Drug Administration. FDA News Release: FDA Approves New Type of Sleep Drug. Belsomra; 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm. Accessed March 17, 2015.
2. Parker T. Merck enters the Insomnia market through the launch of Belsomra in Japan. GlobalData Website; 2014. Available from: http://healthcare.globaldata.com/resources/expert-insights/pharmaceuticals/merck-enters-the-insomnia-market-through-the-launch-of-belsomra-in-japan. Accessed May 12, 2015.
3. United States Food and Drug Administration. FDA drug safety com­munication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs con­taining zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist); 2013. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf. Accessed March 17, 2015.
4. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
5. The National Sleep Foundation. 2014 Sleep Health Index™; 2014. Available from: http://sleepfoundation.org/sleep-health-index
6. Sarsour K, Kalsekar A, Swindle R, Foley K, Walsh JK. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep. 2011;34(4):443–450.
7. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep. 2012;35(6):825–834.
8. Winrow CJ, Renger JJ. Discovery and development of orexin recep­tor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171(2):283–293.
9. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322–327.
10. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–585.
11. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996–10015.
12. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365–376.
13. Foutz AS, Mitler MM, Cavalli-Sforza LL, Dement WC. Genetic factors in canine narcolepsy. Sleep. 1979;1(4):413–421.
14. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40.
15. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25:6716–6720.
16. Knudsen S, Gameltoft S, Jennum PJ. Rapid eye movement sleep behav­iour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. Brain. 2010;133(pt 2):568–579.
17. Broberger C, De Lecea L, Sutcliffe JG, Hӧkfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuro­peptide Y and agouti gene-related protein systems. J Comp Neurol. 1998;402(4):460–474.
18. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53(14):5320–5332.
19. Raheem IT, Breslin MJ, Bruno J, et al. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorg Med Chem Lett. 2015;25(3):444–450.
20. Roecker AJ, Mercer SP, Bergman JM, et al. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorg Med Chem Lett. 2015. [Epub ahead of print]
21. Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol. 2014;171(2):332–350.
22. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2014. [Epub ahead of print]
23. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–471.
24. Margaretten N, Herring WJ, Michelson D; for Merck, Sharp, & Dohme Corporation. Merck Sharp and Dohme Presentations for the May 22, 2013 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM354216.pdf. At U.S. FDA, Slides for the May 22, 2013
25. Meet­ing of the Peripheral and Central Nervous System Drugs Advisory Committee. 2013 Meeting Materials, Peripheral and Central Nervous System Drugs Advisory Committee. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ucm354213.htm. Accessed March 17, 2015.
26. Farkins R, for U.S. FDA. FDA Presentations for the May 22, 2013 Meeting of the Peripheral and Central Nervous System Drugs Advi­sory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateDrugs/Peripheraland­CentralNervousSystemDrugsAdvisoryCommittee/UCM354215.pdf. At U.S. FDA, Slides for the May 22, 2013
27. Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMateri­als/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCom­mittee/ucm354213.htm. Accessed March 17, 2015.
28. Merck, Sharp, & Dohme. Belsomra (Suvorexant): Full Prescribing Information; 2014. Available from: https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf. Accessed March 17, 2015.
29. Lexicomp Online. Suvorexant: Drug Information. Hudson, OH: Lexi-Comp, Inc; 2014.
30. Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955–965.
31. Frauscher B, Ehrmann L, Mitterling T, et al. Delayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysom­nographic analysis of 100 patients of the Innsbruck narcolepsy cohort. J Clin Sleep Med. 2013;9(8):805–812.
32. Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep. 2013;36(3):325–336.
33. Nevsimalova S, Prihodova I, Kemlink D, Lin L, Mignot E. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med. 2007;8:784–786.
34. Bruni O, Verrillo E, Novelli L, Ferri R. Prader-Willi syndrome: sorting out the relationships between obesity, hypersomnia, and sleep apnea. Curr Opin Pulm Med. 2010;16(6):568–573.
35. Blecher G, Wainbergas N, McGlynn M, Teng A. Rapidly evolving narcolepsy-like syndrome coinciding with severe OSA following pharyngoplasty in Prader-Willi syndrome. Respirol Case Rep. 2014;2(3):111–112.
36. Sedky K, Bennett DS, Pumariega A. Prader Willi syndrome and obstruc­tive sleep apnea: co-occurrence in the pediatric population. J Clin Sleep Med. 2014;10(4):403–409.
37. Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep. 2004;27(2):317–321.
38. McCarter SJ, St Louis EK, Sandness DJ, et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behav­ior disorder. Sleep. 2015;38(6):907–917.
39. Frauscher B, Jennum P, Ju YE, et al. Comorbidity and medication in REM sleep behavior disorder: a multicenter case-control study. Neurology. 2014;82(12):1076–1079.
40. Sharpless BA, Barber JP. Lifetime prevalence rates of sleep paralysis: a systematic review. Sleep Med Rev. 2011;15(5):311–315.
41. Bell CC, Shakoor B, Thompson B, et al. Prevalence of isolated sleep paralysis in black subjects. J Natl Med Assoc. 1984;76(5):501–508.
42. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–1562.
43. D’Cruz OF, Vaughn BV, Gold SH, Greenwood RS. Symptomatic cata­plexy in pontomedullary lesions. Neurology. 1994;44(11):2189–2191. [Erratum in: Neurology 1995;45(11):2123].
44. Reynolds TQ, Roy A. Isolated cataplexy and REM sleep behavior disorder after pontine stroke. J Clin Sleep Med. 2011;7(2):211–213.
45. van Dijk JG, Lammers GJ, Blansjaar BA. Isolated cataplexy of more than 40 years’ duration. Br J Psychiatry. 1991;159:719–721.
46. Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci. 2014;8:8.
47. Betschart C, Hintermann S, Behnke D, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem. 2013;56(19):7590–7607.
48. Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–762.
49. Nightingale S, Orgill JC, Ebrahim IO, de Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med. 2005;6(3):253–258.
50. Sun H, Palcza J, Rosenberg R, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(3):416–426.
51. Muraki M, Kitaguchi S, Ichihashi H, et al. Apnoea-hypopnoea index during rapid eye movement and non-rapid eye movement sleep in obstructive sleep apnoea. J Int Med Res. 2008;36(5):906–913.
52. Loadsman JA, Wilcox I. Is obstructive sleep apnoea a rapid eye movement-predominant phenomenon? Br J Anaesth. 2000;85(3):354–358.
53. Jennum P, Ibsen R, Knudsen S, Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep. 2013;36(6):835–840.
54. Han F. Respiratory regulation in narcolepsy. Sleep Breath. 2012;16(1):241–245.
55. Terada J, Nakamura A, Zhang W, et al. Ventilatory long-term facilita­tion in mice can be observed during both sleep and wake periods and depends on orexin. J Appl Physiol(1985). 2008;104(2):499–507.
56. Gill JM, Lee H, Baxter T, et al. A diagnosis of insomnia is associated with differential expression of sleep-regulating genes in military per­sonnel. Biol Res Nurs. 2015;17(4):384–392.
57. Prober DA, Rihel J, Onah AA, Sung RJ, Schier AF. Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26(51):13400–13410.
58. Zisapel N. Current phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015;24(3):401–411.
59. Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics. 2012;9(4):728–738.
60. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and syn­thetic melatoninergic agonists. Neuropsychiatr Dis Treat. 2009;5:341–354.
61. Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012;24(3):215–224.